JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at 24 ...
Two different drugs that target the Janus kinase (JAK) pathway have shown promise for alopecia areata (AA), inducing hair growth in a large proportion of participants in two separate small studies.
PARIS — Long-term results from the ALLEGRO clinical trial program of Pfizer’s JAK inhibitor ritlecitinib for severe alopecia areata showed that complete scalp regrowth occurred in a good proportion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results